January 5, 2022 — Biotech Showcase is an investor conference that aims to connect global life science executives with investors. The event was scheduled to take place January 10-13, 2022, in San Francisco; however, on December 16, 2021, the event’s organizers announced that it would transition to a virtual on-demand platform.
Over 300 companies are presenting at the virtual event this year, including the following companies:
- Brainstorm Cell Therapeutics will present a corporate and clinical overview, which will be delivered by Dr. Ralph Kern, president and chief medical officer (CMO) of Brainstorm. The company’s NurOwn platform for autologous mesenchymal stem cells-multiple neurotrophic factors cells is an investigational approach that is designed to target disease pathways in neurodegenerative diseases.
- Citius Pharmaceuticals will provide updates on two of its late-stage products: Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, and I/Ontak, a novel IL-2R immunotherapy for initial indication in cutaneous T-cell lymphoma.
- Genprex, represented by Rodney Varner, president and CEO, and Dr. Mark Berger, CMO, will present updates on its gene therapies for cancer and diabetes.
- ImmunoGenesis will discuss the company’s immuno-oncology therapeutic development programs which target immune-excluded cancers. ImmunoGenesis’ programs include IMGS-001, a PD-L1/PD-L2 dual-specific inhibitor, and IMGS-501, a novel platform PD-L1/PD-L2 inhibitor that conjugates a STING agonist with optimal PD-1 pathway blockade.
- Nanobiotix will review updates to its physics-based therapeutic approaches and NBTXR3, a novel product candidate that is designed to destroy tumors through physical cell death when activated by radiotherapy.
- NeoImmuneTech will speak about new developments relating to its lead candidate, NT-I7, a long-acting human IL-7 that benefits from T cell amplification and enhanced functionality.
- PharmAbcine, represented by CEO Dr. Jin-San Yoo, will discuss the company’s main pipeline candidates, olinvacimab, an anti-VEGFR2 fully human antibody; PMC-403, a Tie2-activating fully human antibody; and PMC-309, an anti-VISTA antagonizing antibody.
- Last, Transgene will update attendees on clinical programs for two therapeutic vaccines: TG4001, which is targeted for the treatment of human papilloma virus-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform. In addition, the company will discuss new developments relating to its two oncolytic viruses: TG6002, which is for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform.